Ptc Therapeutics (PTCT) Operating Leases (2019 - 2025)
Ptc Therapeutics (PTCT) has 7 years of Operating Leases data on record, last reported at $106.1 million in Q4 2025.
- For Q4 2025, Operating Leases rose 41.52% year-over-year to $106.1 million; the TTM value through Dec 2025 reached $106.1 million, up 41.52%, while the annual FY2025 figure was $106.1 million, 41.52% up from the prior year.
- Operating Leases reached $106.1 million in Q4 2025 per PTCT's latest filing, down from $107.3 million in the prior quarter.
- Across five years, Operating Leases topped out at $146.3 million in Q2 2022 and bottomed at $73.6 million in Q1 2025.
- Average Operating Leases over 5 years is $97.5 million, with a median of $99.2 million recorded in 2022.
- Peak YoY movement for Operating Leases: surged 48.38% in 2022, then tumbled 38.4% in 2025.
- A 5-year view of Operating Leases shows it stood at $73.6 million in 2021, then skyrocketed by 37.0% to $100.9 million in 2022, then fell by 3.21% to $97.6 million in 2023, then fell by 23.23% to $74.9 million in 2024, then soared by 41.52% to $106.1 million in 2025.
- Per Business Quant database, its latest 3 readings for Operating Leases were $106.1 million in Q4 2025, $107.3 million in Q3 2025, and $83.0 million in Q2 2025.